MetaCap

Altria Group (MO) vs Orchestra BioMed (OBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Orchestra BioMed (OBIO) has outperformed Altria Group (MO) over the past year, gaining 45.3% versus a gain of 28.7%. Over five years, MO leads with a +71.2% price change compared with -33.3% for OBIO. Altria Group is the larger company by market cap ($124.54 billion vs $517.9 million), about 240.5 times the size, while Orchestra BioMed is growing revenue faster (+1169.2% vs -3.1%).

Altria Group pays a dividend yielding 5.73%, while Orchestra BioMed does not currently pay one. Altria Group converts more of its revenue into profit, with a net margin of 29.8% versus -157.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MO+28.66%OBIO+45.25%
+69%+21%-27%
Nov 21, 20251 yearNov 20, 2026
MO+72.51%OBIO-33.27%
+127%+21%-85%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MO versus OBIO key metrics
MetricMOOBIO
Share price$74.87$6.58
Market cap$124.54B$517.88M
1-day change+0.25%-6.00%
YTD return+29.85%+58.55%
1-year return+28.66%+45.25%
5-year return+71.17%-33.27%
P/E ratio (TTM)15.44—
Forward P/E12.64—
EPS (TTM)$4.85$-0.75
Dividend yield5.73%0.00%
Annual dividend$4.29$0.00
Revenue (latest FY)$23.28B$33.48M
Revenue growth (YoY)-3.08%+1169.22%
Net income (latest FY)$6.95B$-52.70M
Gross margin62.47%99.43%
Operating margin42.52%-154.73%
Net margin29.84%-157.40%
52-week high$79.97$7.83
52-week low$54.70$3.46
Distance from 52-week high-6.38%-15.91%
Analyst consensusholdstrong_buy
Avg. price target upside-1.90%+101.98%
Average volume8.05M420.19K
Shares outstanding1.66B78.70M
Employees5,90086
SectorHealth CareHealth Care
Industry Medicinal Chemicals and Botanical Products Medicinal Chemicals and Botanical Products

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Altria Group is about 240.5 times larger than Orchestra BioMed by market value ($124.54B vs $517.88M).
  • OBIO has outperformed MO by 16.6 percentage points over the past year.
  • Altria Group offers a meaningfully higher dividend yield (5.73% vs 0.00%).
  • Altria Group is more profitable, keeping 29.8 cents of every revenue dollar as net income versus -157.4 cents for Orchestra BioMed.
  • Orchestra BioMed grew revenue faster in its latest fiscal year (+1169.22% vs -3.08%).

About Altria Group

MO stock →

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. It offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and oral tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand.

Health Care · Medicinal Chemicals and Botanical Products · 5,900 employees

About Orchestra BioMed

OBIO stock →

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.

Health Care · Medicinal Chemicals and Botanical Products · 86 employees

MO vs OBIO FAQ

Which is bigger, Altria Group or Orchestra BioMed?

Altria Group (MO) is larger, with a market capitalization of $124.54B compared with $517.88M for Orchestra BioMed (OBIO).

Which stock has performed better over the past year, MO or OBIO?

OBIO returned +45.25% over the past 12 months, compared with +28.66% for MO (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Altria Group or Orchestra BioMed?

Altria Group pays a dividend yielding 5.73%, while Orchestra BioMed does not currently pay a regular dividend.

Are Altria Group and Orchestra BioMed in the same industry?

Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.

More comparisons